Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284141 | 0.89 | APLNR (0.55) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL11525177 | 0.84 | MEN1 (0.56) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL24514107 | 0.82 | APLNR (0.50) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL25198094 | 0.81 | APLNR (0.46) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL1717954 | 0.80 | APLNR (0.48) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL19273270 | 0.80 | APLNR (0.48) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL3403411 | 0.79 | APLNR (0.49) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL4150198 | 0.79 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL8520807 | 0.79 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL3709746 | 0.78 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110066286-B | Phenylpyrazoline compound with biological activity and preparation method and application thereof | 湖南化工研究院有限公司 | 2020-06-16 | — | — | CN | claimed |
| US-7138416-B2 | Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate | TORRENT PHARMACEUTICALS LTD. (IN) | 2006-11-21 | — | — | US | claimed |
| EP-1492777-A1 | THIAZOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDASE INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | claimed |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2004-06-03 | — | — | US | claimed |
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-12-04 | — | — | US | claimed |
| WO-2003084940-A1 | THIAZOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDAS INHIBITORS | SANKARANARAYANAN ALANGUDI (IN) | 2003-10-16 | — | — | WO | claimed |
| EP-4696329-A1 | ANTI-ROR1 ANTIBODY AND DRUG CONJUGATE THEREOF | BioRay Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023212650-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4134367-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-15 | — | — | EP | disclosed |
| EP-3983386-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-0836618-A1 | RADIOMETAL-BINDING ANALOGUES OF LEUTENIZING HORMONE RELEASING HORMONE | Immunomedics, Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997035199-A9 | AZATIDE PEPTIDOMIMETICS | — | 1997-12-11 | — | — | WO | disclosed |
| WO-1997035199-A1 | AZATIDE PEPTIDOMIMETICS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-09-25 | — | — | WO | disclosed |
| WO-1996040756-A1 | RADIOMETAL-BINDING ANALOGUES OF LEUTENIZING HORMONE RELEASING HORMONE | IMMUNOMEDICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5494889-A | THIADIAZABICYCLOOCTANE AND THIADIAZABICYCLOOCTENE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1996-02-27 | — | — | US | disclosed |
| US-5416065-A | Herbicidal thiadiazabicyclooctanes | CIBA-GEIGY CORPORATION (US) | 1995-05-16 | — | — | US | disclosed |
| WO-1992021684-A1 | NEW HERBICIDES | CIBA-GEIGY AG (CH) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A4 | APLNR 2827/4885GAA 424/4885MEN1 2227/4885 |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A3 | APLNR 1346/4885GAA 344/4885MEN1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.